Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results ...

Shares fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant’s ...

The implications for Eli Lilly and Novo Nordisk seem pretty clear: The immediate removal of a rival for the massive revenues ...

Eli Lilly reports positive late-stage data for its weight-loss pill. BMO analyst says Lilly's update will weigh on shares of ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

Eli Lilly announced clinical trial results this week for a daily pill to treat obesity and diabetes. Its name is absolutely ...

Novo Nordisk A/S slumped after a pill from rival Eli Lilly & Co. helped patients shed weight and control blood sugar about as ...

Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...